1-(甲氧基甲基)环丙烷-1-甲醛 | 1097875-89-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(甲氧基甲基)环丙烷-1-甲醛
• 英文名称: 1-(Methoxymethyl)cyclopropane-1-carbaldehyde
• CAS: 1097875-89-2
• 化学式: C₆H₁₀O₂
• 分子量: 114.14
• InChiKey: GDYUGWFFKOKCFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel triazolopyridazines
  申请人：Calderwood David J.

  公开号：US20090270402A1

  公开（公告）日：2009-10-29

  The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

  本发明涉及式（I）的新化合物，其中变量如此定义。式（I）的化合物可用作激酶抑制剂，在治疗某些情况和疾病方面非常有用，特别是在治疗炎症性疾病和增殖性疾病和情况，例如癌症。
• NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1889836A1

  公开（公告）日：2008-02-20

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]

  下式代表的化合物、其盐或前述化合物的水合物具有极佳的肝细胞生长因子受体（HGFR）抑制活性，并具有抗肿瘤活性、血管生成抑制活性和癌症转移抑制活性。 [R1 代表 3 至 10 元的非芳香杂环基团或类似基团；R2 和 R3 代表氢；R4、R5、R6 和 R7 可以相同或不同，各自代表氢、卤素、C1-6 烷基或类似基团；R8 代表氢或类似基团；R9 代表 3 至 10 元的非芳香杂环基团或类似基团；n 代表 1 或 2 的整数；X 代表 -CH=、氮或类似基团。］
• PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2119706A1

  公开（公告）日：2009-11-18

  A pyridine or pyrimidine derivative represented by the formula (I) has an excellent HGFR inhibitory activity and exhibits strong cell proliferation inhibitory effect and anti-tumor effect against cancer cell lines with amplified HGFR gene. wherein R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen.

  由式（I）代表的吡啶或嘧啶衍生物具有极佳的 HGFR 抑制活性，对 HGFR 基因扩增的癌细胞株有很强的细胞增殖抑制作用和抗肿瘤作用。 其中 R1 代表 3 至 10 元的非芳香杂环基团或类似物；R2 和 R3 代表氢；R4、R5、R6 和 R7 可以相同或不同，各自代表氢、卤素、C1-6 烷基或类似物；R8 代表氢或类似物；R9 代表 3 至 10 元的非芳香杂环基团或类似物；n 代表 1 或 2 的整数；X 代表-CH=、氮。
• PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
  申请人：Forma Therapeutics, Inc.

  公开号：EP3483164B1

  公开（公告）日：2020-03-04
• INHIBITORS OF APOL1 AND METHODS OF USING SAME
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20220106327A1

  公开（公告）日：2022-04-07

  The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).